Bioxytran (BIXT) 10-Q 13 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 12, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	BIOXYTRAN, INC
Entity Central Index Key	0001445815
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		86,475,673
Entity File Number	001-35027
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	NV

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 33,226	$ 36,411
Total current assets	33,226	36,411
Total assets	33,226	36,411
Current liabilities:
Accounts payable and accrued expenses	92,169	23,447
Accounts payable related party		10,900
Un-issued shares liability	532,418
Convertible notes payable (net of discount of $13,248 and $22,622, and premium of $102,527 and $0, respectively)	589,279	227,378
Total current liabilities	1,213,866	261,725
Total liabilities	1,213,866	261,725
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 50,000,000 shares authorized, nil issued and outstanding
Common stock, $0.001 par value; 300,000,000 shares authorized; 85,306,673 and 85,103,673 shares issued and outstanding, respectively	85,307	85,104
Additional paid-in capital	312,701	72,412
Accumulated deficit	(1,578,648)	(382,830)
Total stockholders' equity (deficit)	(1,180,640)	(225,314)
Total liabilities and stockholders' equity (deficit)	$ 33,226	$ 36,411

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Convertible notes payable, net of discount	$ 13,248	$ 22,622
Convertible notes payable, Premium	$ 102,527	$ 0
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	85,306,673	85,103,673
Common stock, shares outstanding	85,306,673	85,103,673

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating expenses:
General and administrative	$ 54,242	$ 47,524	$ 289,866	$ 48,469
Compensation expense	796,077		841,937
Total operating expenses	850,319	47,524	1,131,803	48,469
Loss from operations	(850,319)	(47,524)	(1,131,803)	(48,469)
Other (expenses):
Interest expense	(10,002)		(26,891)
Debt discount amortization	(13,794)		(37,124)
Total other (expenses)	(23,796)		(64,015)
Net loss before provision for income taxes	(874,115)	(47,524)	(1,195,818)	(48,469)
Provision for income taxes
NET LOSS	$ (874,115)	$ (47,524)	$ (1,195,818)	$ (48,469)
Loss per common share, basic and diluted	$ (0.01)	$ 0	$ (0.01)	$ 0
Weighted average number of common shares outstanding, basic and diluted	85,198,032	85,103,673	85,138,310	85,103,673

Condensed Consolidated Changes

Condensed Consolidated Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock	Preferred Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2017	$ 85,104			$ (86,413)	$ (1,309)
Balance, shares at Dec. 31, 2017	85,103,673
Common stock, shares authorized	300,000,000
Preferred stock, shares authorized		50,000,000
Net loss
Balance at Mar. 31, 2018	$ 85,104			(89,413)	(1,309)
Balance, shares at Mar. 31, 2018	85,103,673
Net loss				(945)	(945)
Balance at Jun. 30, 2018	$ 85,104			(87,083)	(1,979)
Balance, shares at Jun. 30, 2018	85,103,673
Net loss				(47,524)	(47,524)
Balance at Sep. 30, 2018	$ 85,104			(134,882)	(49,778)
Balance, shares at Sep. 30, 2018	85,103,673
Issuance of warrants			45,361		45,361
Debt premium			(343,796)		(343,796)
Debt premium accretion			60,268		60,268
Net loss				(191,409)	(191,409)
Balance at Mar. 31, 2019			(165,755)	(574,239)	(654,890)
Debt premium accretion			123,276		123,276
Shares issued for conversion of accrued interest	$ 25		4,975		5,000
Shares issued for conversion of accrued interest, shares	25,000
Net loss				(130,294)	(130,294)
Balance at Jun. 30, 2019	$ 85,129		(37,504)	(704,533)	(656,908)
Balance, shares at Jun. 30, 2019	85,128,673
Options issued - 2010 Plan			228,058		228,058
Shares issued - 2010 Plan	$ 108		34,492		34,600
Shares issued - 2010 Plan, shares	108,000
Debt premium			(82,500)		(82,500)
Debt premium accretion			140,225		140,225
Shares issued for conversion of accrued interest	$ 50		9,950		10,000
Shares issued for conversion of accrued interest, shares	50,000
Shares issued for cash	$ 20		19,980		20,000
Shares issued for cash, shares	20,000
Net loss				(874,115)	(874,115)
Balance at Sep. 30, 2019	$ 85,307		$ 312,701	$ (1,578,648)	$ (1,180,640)
Balance, shares at Sep. 30, 2019	85,306,673

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,195,818)	$ (48,469)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	37,124
Stock-based compensation expense	840,438
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	83,722	45,262
Accounts payable related party	(10,900)	5,928
Net cash provided by (used) in operating activities	(245,435)	2,721
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	20,000
Proceeds from issuance of convertible notes payable	222,250
Net cash provided by financing activities	242,250
Net increase (decrease) in cash	(3,185)	2,721
Cash, beginning of period	36,411	110
Cash, end of period	33,226	2,831
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid
Income taxes paid
NON-CASH INVESTING & FINANCING ACTIVITIES
Debt discount on convertible note	37,124
Debt premium on convertible note	426,296
Accretion of debt premium to additional paid-in capital	(323,769)
Common shares issued for the conversion of accrued interest	$ 15,000

Background and Organization

Background and Organization	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BACKGROUND AND ORGANIZATION	NOTE 1 – BACKGROUND AND ORGANIZATION Business Operations Bioxytran, Inc. (the "Company") is an early-stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues, in a safe and efficient manner. If it is not addressed, lack of oxygen to tissues, or hypoxia, results in necrosis, which is the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications to include treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. The Company's initial focus is the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. We believe that ours is a novel approach that will result in the creation of safe drug alternatives to existing therapies for effectively addressing hypoxic conditions in humans. Our drug development efforts are guided by specialists in co-polymer chemistry and other disciplines, and we intend to supplement our efforts with input from a scientific and medical advisory board whose members are leading physicians. Organization Bioxytan, Inc. was organized on October 5, 2017 as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 authorized common shares with a par value of $0.0001, and 5,000,000 preferred shares with a par value of $0.0001. On September 21, 2018, the Company went under a reorganization in form of a reverse merger and is currently registered as a Nevada corporation with a taxing structure for U.S. federal and state income tax as a C-Corporation with 300,000,000 authorized common shares with a par value of $0.001, and 50,000,000 preferred shares with a par value of $0.001 Basis of Presentation The summary of significant accounting policies presented below is designed to assist in understanding the Company's consolidated financial statements. Such financial statements and accompanying notes are the representations of the Company's management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") in all material respects and have been consistently applied in preparing the accompanying financial statements. The Company has not earned any revenue from operations since inception. The Company chose December 31 st The accompanying unaudited financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim financial statements be read in conjunction with the Company's audited financial statements and notes thereto included in its Form 10-K for the year ended December 31, 2018. Operating results for the nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Bioxytran, Inc. a Nevada Corporation and its wholly owned subsidiary, Bioxytran, Inc. of Delaware (collectively, the "Company"). All intercompany accounts have been eliminated upon consolidation.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows. Cash For purposes of the Statement of Cash Flows, the Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company's stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share ("ASC 260-10"). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the "treasury stock" and/or "if converted" methods as applicable. There are 416,666 warrants and 293,000 options outstanding at September 30, 2019 (Note 6), as well as 463,000 common shares that have been allocated to short-term liabilities for future issuance (see Stock-Based Compensation below). There are 208,333 warrants outstanding at December 31, 2018. These potentially dilutive securities are not presented in the attached financial statements, as their effect would be anti-dilutive. Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award on the grant date Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of September 30, 2019, there were 293,000 outstanding stock options with a fair market value of $228,058 and 108,000 shares issued with a fair market value of $34,600 at the time of award. An additional 463,000 shares with a fair Market Value of $532,418 at the time of award, had not yet been issued on September 30, 2019, and are allocated to Current Liabilities (Note 4). At December 31, 2018, there were no outstanding stock options, nor any shares awarded. Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. During the nine months ended September 30, 2019 and September 30, 2018 the Company did not incur significant research and development expenses. Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10") requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures ("ASC 820-10") and Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10"), which permits entities to choose to measure many financial instruments and certain other items at fair value. Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

Going Concern and Management's

Going Concern and Management's Liquidity Plans	9 Months Ended
	Sep. 30, 2019
Going Concern and Management's Liquidity Plans [Abstract]
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	NOTE 3 – GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS As of September 30, 2019, the Company had cash of $33,226 and a negative working capital of $1,180,640. As of September 30, 2019, the Company has not yet generated any revenues, and has incurred cumulative net losses of $1,578,648. These conditions raise substantial doubt about the Company's ability to continue as a going concern. During the nine months ending September 30, 2019, the Company has raised a net of $222,250 from issuance of debt in form of convertible notes, and $20,000 in cash proceeds from the issuance of common stock. There were no funds raised during the same period in 2018. The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of December 2019 and is pursuing alternative opportunities to funding. The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.

Accounts Payables and Accrued E

Accounts Payables and Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2019
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 4 – ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES On September 30, 2018, there was no Accrued Expenses in Accounts Payables to related parties. On December 31, 2018 there was $10,900 in form of payroll and advanced expenses. The following table represents the major components of accounts payables and accrued expenses and other current liabilities at September 30, 2019 and December 31, 2018: September 30, December 31, Accounts Payables related party $ - $ 10,900 Professional fees 72,603 19,175 Interest 17,113 3,722 Taxes - 400 Other Accounts Payables 2,453 150 Un-issued shares liability 532,418 - Convertible Note Payables 589,279 227,378 Total $ 1,213,866 $ 261,725

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 5 – CONVERTIBLE NOTES PAYABLE As long as the following convertible notes remain outstanding, the Company cannot amend its charter in any matter that materially effects rights of noteholders, repay or repurchase more than de minimis number of shares of common stock other than conversion or warrant shares, repay or repurchase all or any portion of any indebtedness, or pay cash dividends. Auctus Note #1 On October 24, 2018 (the "Date of Issuance") the Company issued a convertible promissory note (the "Auctus Note #1") with a face value of $250,000, maturing on October 23, 2019, and a stated interest of 8% to a third-party investor. The Auctus Note #1 is convertible into common stock of the Company, par value $.001 per share (the "Common Stock") at any time after the earlier of: (i) 180 days from the date of the Auctus Note #1, or (ii) upon effective date of a registration statement. The conversion price of the Auctus Note #1 is equal to the lesser of: (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #1 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Auctus Note #1 was funded on October 29, 2018, when the Company received proceeds of $222,205, after disbursements for the lender's transaction costs, fees and expenses which in aggregate resulted in a total discount of $27,795 to be amortized to interest expense over the life of the Auctus Note #1. Additionally, the variable conversion rate component requires that the Auctus Note #1 be valued at its stock redemption value (i.e., "if-converted" value) pursuant to ASC 480, Distinguishing Liabilities from Equity Along with the Auctus Note #1, on the Date of Issuance the Company issued 208,333 Common Stock Purchase Warrants (the "Warrants"), exercisable immediately at a fixed exercise price of $0.60 with an expiration date of October 23, 2023. The Company has determined that the Warrants are exempt from derivative accounting and were valued at $101,937 on the Date of Inception using the Black Scholes Options Pricing Model. Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.49 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 251% and (5) risk free interest rate of 2.51%. The note proceeds of $250,000 were then allocated between the fair value of the Auctus Note #1 ($250,000) and the Warrants ($101,937), resulting in a debt discount of $72,412. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance. Auctus Note #2 On February 25, 2019, the Company entered into a $250,000 Senior Secured Promissory Note ("the Auctus Note #2"), dated February 25, 2019 at an interest rate of 8% per annum, maturing on February 24, 2020 (the "Maturity Date"). Issuance fees totaling $27,750 were recorded as a debt discount, resulting in net proceeds of $222,250. The Auctus Note #2 is convertible into common stock of the Company, par value $.001 per share (the "Common Stock") at any time after the earlier of: (i) 180 days from the date of the Auctus Note #2 or (ii) upon effective date of a new registration statement. The conversion price of the Auctus Note #2 is equal to the lesser of: (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #2 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Company may prepay the Auctus Note #2 at any time at a rate of 120% of outstanding principal and interest during the first 90 days it is outstanding and 130% of outstanding principal and interest for the next 90 days thereafter. Thereafter the prepayment amount increases 5% for each thirty-day period until 270 days from the issue date at which time it is fixed at 150% of the outstanding principal and interest on the Auctus Note #2. Additionally, the variable conversion rate component requires that the Auctus Note #2 be valued at its stock redemption value (i.e., "if-converted" value) pursuant to ASC 480, Distinguishing Liabilities from Equity, with the excess over the undiscounted face value being deemed a premium to be added to the principal balance and accreted to additional paid-in capital over the life of the Auctus Note #2. As such, the Company recorded a premium of $82,500 as a reduction to additional paid-in capital based on a discounted "if-converted" rate of $0.20 per share (lowest trading price during the 20 days preceding the note's issuance), which computed to 1,250,000 shares of 'if-converted' common stock with a redemption value of $332,500 due to $0.266 per share fair market value of the Company's stock on the Auctus Note #2's date of issuance. Debt discount amortization is recorded as interest expense, while debt premium accretion is recorded as an increase to additional paid-in capital. During the nine months ended September 30, 2019, the Company amortized $16,271 debt discount to operations as interest expense, and accreted $16,949 of premium to additional paid-in capital. Along with the the Auctus Note #2, on the Date of Issuance the Company issued 208,333 Common Stock Purchase Warrants (the "Warrants"), exercisable immediately at a fixed exercise price of $0.60 with an expiration date of February 24, 2024. The Company has determined that the Warrants are exempt from derivative accounting and were valued at $55,417 on the Date of Inception using the Black Scholes Options Pricing Model. Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.27 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 358% and (5) risk free interest rate of 2.48%. The Auctus Note #2 proceeds of $250,000 were then allocated between the fair value of the Auctus Note #2 ($250,000) and the Warrants ($55,417), resulting in a debt discount of $45,361. As the warrants are exercisable immediately, this debt discount was amortized in its entirety to issuance of warrants (other expenses) on the Date of Issuance. Convertible notes payable consists of the following at September 30, 2019 and December 31, 2018: September 30, December 31, Principal balance $ 500,000 $ 250,000 Unamortized debt discount (13,248 ) (22,622 ) Unamortized debt premium 102,527 - Outstanding, net of debt discount and premium $ 589,279 $ 227,378

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 6 – STOCKHOLDERS' EQUITY At a Board of Director's Meeting on July 30, 2018, the Company authorized a reverse split that resulted in a reduction of the number of outstanding and issued shares of both common and preferred stock so that after the split became effective on August 13, 2018, the shares of both common and preferred stock were reduced to 1 share for each 30 shares currently issued and outstanding. The effect on the Balance Sheet is a transfer of value from stock value at par to Additional Paid-in Capital. As a result of the one (1) for thirty (30) reverse stock split, the Company will continue to be authorized to issue 300,000,000 shares of Common Stock, and 50,000,000 shares of Preferred Stock. The reverse split has been retroactively applied to all periods presented. Preferred stock As of September 30, 2019, no preferred shares have been designated or issued. Common stock On May 30, 2019, 25,000 shares of common stock were issued as a result of conversion of accrued interest on the Auctus Note #1 at $0.20 per share for a total of $5,000. For details, see Convertible Note Payable under Note 3. On July 18, 2019, 25,000 shares of common stock were issued as a result of conversion of accrued interest on the Auctus Note #1 at $0.20 per share for a total of $5,000. For details, see Convertible Note Payable under Note 3. On August 20, 2019, 20,000 shares of common stock were sold and issued from the active S-1 at $1 per share for a total of $20,000. On August 22, 2019, 25,000 shares of common stock were issued as a result of conversion of accrued interest on the Auctus Note #1 at $0.20 per share for a total of $5,000. For details, see Convertible Note Payable under Note 3. Between November 2, 2018, and May 17, 2019, 108,000 shares were awarded with an average cost per share of $0.32, under the 2010 Stock Plan for a total value of $34,600. The shares were issued on September 3, 2019. For details, see Shares Awarded and Issued under Note 5. As of September 30, 2019, the Company has 85,306,673 shares of common stock issued and outstanding. Common Stock Options/Warrants On February 25, 2019 the Company issued 208,333 Warrants as part of a convertible note agreement. The warrants total value allocated to debt discount was $45,361. For details, see Convertible Note Payable under Note 3. The following table summarizes the Company's common stock warrant and options activity for the nine months ended September 30, 2019 and the year ended December 31, 2018: Weighted Weighted- Warrants/ Exercise Expected Outstanding as of January 1, 2018 - $ - - Granted 208,333 0.60 5.0 Exercised - - - Forfeited/Canceled - - - Outstanding as of December 31, 2018 208,333 $ 0.60 4.8 Granted 208,333 0.60 5.0 Exercised - - - Forfeited/Canceled - - - Outstanding as of September 30, 2019 416,666 $ 0.60 4.2 Between May 1 and July 9, 2019, 293,000 options were awarded under the 2010 Stock Option Plan. The options were issued on September 3, 2019. The options total fair value at the time of award was $228,058. For details, see Stock options granted under Note 5. The following table summarizes the Company's common stock warrant and options activity for the nine months ended September 30, 2019 and the year ended December 31, 2018: Weighted Weighted- Warrants/ Exercise Expected Outstanding as of January 1, 2018 - $ - - Granted - - - Exercised - - - Forfeited/Canceled - - - Outstanding as of December 31, 2018 - $ - - Granted 293,000 1.01 3.0 Exercised - - - Forfeited/Canceled - - - Outstanding as of September 30, 2019 293,000 $ 1.01 2.9

Stock Option Plan and Stock-Bas

Stock Option Plan and Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION	NOTE 7 – STOCK OPTION PLAN AND STOCK-BASED COMPENSATION During the year ended December 31, 2010, the Company adopted a stock option plan entitled "The 2010 Stock Plan" (2010 Plan) under which the Company may grant Options to Purchase Stock, Stock Awards or Stock Appreciation Rights up to 15% of common stock, automatically adjusted on January 1 each year. As of December 31, 2018, there were no outstanding awards under the 2010 Plan. As of September 30, 2019, there were 293,000 outstanding stock options with a fair market value of $228,058 and 108,000 shares issued with a fair market value of $34,600 at the time of award. An additional 463,000 shares with a fair Market Value of $532,418 at the time of award, had not yet been issued on September 30, 2019, and are allocated to Current Liabilities (Note 4). At December 31, 2018, there were no outstanding stock options, nor any shares awarded. Under the terms of the stock plans, the Board of Directors shall specify the exercise price and vesting period of each stock option on the grant date. Vesting of the options is typically immediate and the options typically expire in five years. Stock Awards may be directly issued under the Plan (without any intervening options). Stock Awards may be issued which are fully and immediately vested upon issuance. Shares Awarded and Issued: On November 2, 2018, the Company granted 4,000 shares with a fair market value of $0.51 to four members of the Company Board as compensation for their contribution in the Company's Board of Directors, for a total of $2,040. The shares were issued on September 13, 2019. On March 11, 2019 the Company granted 100,000 shares with a fair market value of $0.27, to a consultant as compensation for their work with the Company's IR, for a total of $26,600. The shares were issued on September 4, 2019. On May 17, 2019, the Company granted 4,000 shares with a fair market value of $1.49 to four members of the Company Board as compensation for their contribution in the Company's Board of Directors, for a total of $5,960. The shares were issued on September 13, 2019. Shares Awarded, but not yet Issued: On November 6, 2018, the Company granted 1,000 shares with a fair market value of $0.52 to one member of the Audit Committee as compensation for his contribution in this Company Committee, for a total of $520. On November 29, 2018, the Company granted 4,000 shares with a fair market value of $1.00 to four members of the Audit Committee as compensation for his contribution in this Company Committee, for a total of $4,000. On March 7, 2019, the Company granted 3,000 shares with a fair market value of $0.27 to three members of the Audit Committee as compensation for his contribution in this Company Committee, for a total of $810. On May 10,2019 the Company granted 3,000 shares with a fair market value of $1.00 to three members of the Audit Committee as compensation for his contribution in this Company Committee, for a total of $3,000. On June 11, 2019 the Company granted 250,000 shares with a fair market value of $1.39 to a Financial Advisory Board Member for his contribution in the Company's Advisory Board, for a total of $347,500. On July 16, 2019 the Company granted 100,000 shares with a fair market value of $1.00 to a Financial Advisory Board Member for his contribution in the Company's Advisory Board, for a total of $100,000. On July 15, 2019 the Company granted 100,000 shares with a fair market value of $0.75 to a Financial Advisory Board Member for his contribution in the Company's Advisory Board, for a total of $75,000. On August 9, 2019, the Company granted 2,000 shares with a fair market value of $0.80 to two members of the Audit Committee as compensation for his contribution in this Company Committee, for a total of $1,600. The fair value of stock awards granted for the nine months ended September 30, 2019 was calculated based on stocks trading value at the date earned. Shares Fair Value Weighted Shares Granted as of December 31, 2018 - $ - $ - Shares Granted 571,000 0.27 - 1.49 0.99 Shares Issued 108,000 0.27 - 1.49 0.32 Shares Granted not Issued as of September 30, 2019 463,000 $ 0.75 - 1.39 $ 1.15 For the three and nine months ended September 30, 2019, the Company recorded stock-based compensation expense of $34,600 and $34,600, respectively, in connection with share-based payment awards. The Company did not record any recorded stock-based compensation expense during 2018. The granted, but not yet registered 463,000 shares for a total of $532,418 were allocated to Current Liabilities. See Un-issued shares liability under Note 4. Stock options granted: On May 1, 2019, the Company granted 45,000 three-year options at an exercise price of $1.21, to a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $44,820. The options were issued on September 3, 2019. On July 1, 2019 the Company granted 3,000 three-year options at an exercise price of $1.09 to a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $2,447. The options were issued on September 3, 2019. On August 1, 2019 the Company granted 45,000 three-year options at an exercise price of $1.10 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $39,731. The options were issued on September 3, 2019. On July 9, 2019 the Company granted 200,000 three-year options at an exercise price of $0.95 to two Financial Advisory Board Members for their contribution in the Company's Advisory Board. The options total fair value at the time of award was $141,060. The options were issued on September 13, 2019. The fair value of stock options granted and revaluation of non-employee consultant options for the nine months ended September 30, 2019 was calculated with the following assumptions: 2019 Risk-free interest rate 1.68 - 2.31 % Expected dividend yield 0 % Volatility factor (weekly) 126.89 % Expected life of option 3 years For the three and nine months ended September 30, 2019, the Company recorded compensation expense of $228,058 and $228,058, respectively, in connection with awarded stock options. The Company did not record any awarded option valuation as compensation expense during 2018. As of September 30, 2019, there was no unrecognized compensation expense related to non-vested stock option awards. The following table summarizes the Company's stock option activity during the nine months ended September 30, 2019: Shares Exercise Weighted Outstanding as of December 31, 2018 - $ - $ - Granted 293,000 0.95 - 1.21 1.01 Exercised - - - Options forfeited/cancelled - - - Outstanding as of September 30, 2019 293,000 $ 0.95 - 1.21 $ 1.01 The following table summarizes information about stock options that are vested or expected to vest at September 30, 2019: Options Outstanding Exercisable Options Exercise Number of Options Weighted Average Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic $ 0.95 200,000 $ 0.95 2.95 $ - 200,000 $ 0.95 2.93 $ - 1.09 3,000 1.09 2.75 - 3,000 1.09 2.75 - 1.10 45,000 1.10 2.84 - 45,000 1.10 2.84 - 1.21 45,000 1.21 2.58 - 45,000 1.21 2.58 - $ 1.03-1.21 293,000 $ 1.01 2.88 $ - 293,000 $ 1.01 2.88 $ - The following table sets forth the status of the Company's non-vested stock options as of September 30, 2019 and December 31, 2018: Number of Weighted- Non-vested as of December 31, 2018 - $ - Granted 293,000 0.78 Forfeited - - Vested 293,000 0.78 Non-vested as of September 30, 2019 - $ - The weighted-average remaining contractual life for options exercisable at September 30, 2019 is 2.88 years. The aggregate intrinsic value for fully vested, exercisable options was $0 at September 30, 2019. The aggregate intrinsic value of options exercised during the nine months ended September 30, 2019 was $0 as no options were exercised. The actual tax benefit realized from stock option exercises during the nine months ended September 30, 2018 was $0 as no options were exercised. At September 30, 2019 the Company has 11,901,551 options or stock awards available for grant under the 2010 Plan.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Employment contracts The Company's executive officers have entered employment contracts and confidentiality, non-disclosure and assignment of invention agreements. The employment agreements do not provide for the payment of any compensation to our executive officers but provide for the payment of $100,000 in severance upon termination of employment without cause and make no provisions for any payment upon a change of control. Litigation In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Legal fees for such matters are expensed as incurred and we accrue for adverse outcomes as they become probable and estimable.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 – SUBSEQUENT EVENTS The Company has evaluated events from September 30, 2019 through the date the financial statements were issued. The events requiring disclosure for this period are as follows; Options and stock awards granted as under the 2010 Stock Plan: On October 1, 2019 the Company granted 3,000 three-year options at an exercise price of $0.73 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $1,635. On October 3, 2019 the Company issued 463,000 common shares that had been allocated to short-term liabilities for future issuance for a total value of $532,418. On October 17, 2019 the Company granted 3,000 shares with a fair market value of $0.60 to four members of the Company Board as compensation for their contribution in the Company's Board of Directors, for a total of $1,800. On October 21, 2019 the Company granted 300,000 shares with a fair market value of $0.55 at the time of award, to a consultant as compensation for their work with the Company's IR, for a total of $166,283. On November 1, 2019 the Company granted 45,000 three-year options at an exercise price of $0.61 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $27.450. On November 8, 2019 the Company granted 3,000 shares with a fair market value of $0.65 to four members of the Company Board as compensation for their contribution in the Company's Board of Directors, for a total of $1,950. On November 11, 2019 the Company signed an Investor Relations ("IR") agreement with FON Consulting LLC ("FON"). As part of the contract the Company granted FON 250,000 shares with a fair market value of $0.51 at the time of award, as compensation for their work with the Company's IR, for a total of $127,500. Common shares issued On October 8, 2019, 50,000 shares of common stock were issued as a result of conversion of principal as well as accrued interest on the Auctus Note #1 at $0.20 per share for a total of $10,000. For details, see Convertible Note Payable under Note 3. On November 8, 2019, 100,000 shares of common stock were issued as a result of conversion of accrued interest on the Auctus Note #2 at $0.12 per share for a total of $12,000. For details, see Convertible Note Payable under Note 3. Other subsequent events In the period October 23, 2019 through November 8, 2019, the Company entered into four separate Secured Promissory Note Agreements ("SPA") with a face value of $457,300, and received net proceeds of $412,500. The Notes are convertible into common stock of the Company, par value $.001 per share (the "Common Stock") at any time after the earlier of: (i) 180 days from the date of the Note or (ii) upon effective date of a registration statement. The conversion price of the Notes is equal to 65% of the lowest trading price at close during the twenty days prior to a conversion notice. The debt discount of $44,800 is amortized over the duration of the loans. One of the SPA's includes an option to raise an additional $350,000 in convertible notes. The Debentures permit the Company to pre-pay its obligations at a premium prior to maturity. Further, the Company issued five-year warrants with cashless exercise provisions to purchase a total of 150,000 shares of Common Stock of the Company at an exercise price of $2.00 per share with cashless exercise provisions to three of the Lenders. The Company has determined that the Warrants are exempt from derivative accounting. The note proceeds of $457,300 were then allocated between the fair value of the Notes ($457,300) and the Warrants ($82,200), resulting in a debt discount of resulting in a fully amortized debt discount of $66,589. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance. The proceeds from these Notes were used to pay off the Auctus #1 Note, maturing on October 24,2019, and for working capital. For details, see Convertible Note Payable under Note 3. Debtor Date of Maturity Principal Net Interest Warrants Issued Term Exercise Amortization Debt GS Capital Partners LLC 10/30/2019 10/29/2019 $ 125,000 $ 109,500 4 % 50,000 5 $ 2.00 $ 23,867 $ 15,500 Power Up Lending Group Ltd. 10/24/2019 10/23/2020 106,000 100,000 8 % - - - - 6,000 Peak One Opportunity Fund, L.P. 10/23/2019 10/22/2020 120,000 103,000 0 % 50,000 5 2.00 21,606 17,000 Tangiers Global, LLC 10/23/2019 10/22/2020 106,300 100,000 8 % 50,000 5 2.00 21,116 6,300 $ 457,300 $ 412,500 150,000 $ 66,589 $ 44,800

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Cash	Cash For purposes of the Statement of Cash Flows, the Company considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of expenses during the reporting period. Significant estimates include the fair value of the Company's stock, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Net Loss per Common Share, basic and diluted	Net Loss per Common Share, basic and diluted The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share ("ASC 260-10"). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the "treasury stock" and/or "if converted" methods as applicable. There are 416,666 warrants and 293,000 options outstanding at September 30, 2019 (Note 6), as well as 463,000 common shares that have been allocated to short-term liabilities for future issuance (see Stock-Based Compensation below). There are 208,333 warrants outstanding at December 31, 2018. These potentially dilutive securities are not presented in the attached financial statements, as their effect would be anti-dilutive.
Stock Based Compensation	Stock Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award on the grant date Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of September 30, 2019, there were 293,000 outstanding stock options with a fair market value of $228,058 and 108,000 shares issued with a fair market value of $34,600 at the time of award. An additional 463,000 shares with a fair Market Value of $532,418 at the time of award, had not yet been issued on September 30, 2019, and are allocated to Current Liabilities (Note 4). At December 31, 2018, there were no outstanding stock options, nor any shares awarded.
Research and Development	Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. During the nine months ended September 30, 2019 and September 30, 2018 the Company did not incur significant research and development expenses.
Fair Value	Fair Value Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10") requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures ("ASC 820-10") and Accounting Standards Codification subtopic 825-10, Financial Instruments ("ASC 825-10"), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Recent Accounting Pronouncements	Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

Accounts Payables and Accrued_2

Accounts Payables and Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2019
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
Schedule of accounts payables and accrued expenses and other current liabilities	September 30, December 31, Accounts Payables related party $ - $ 10,900 Professional fees 72,603 19,175 Interest 17,113 3,722 Taxes - 400 Other Accounts Payables 2,453 150 Un-issued shares liability 532,418 - Convertible Note Payables 589,279 227,378 Total $ 1,213,866 $ 261,725

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of convertible notes payable	September 30, December 31, Principal balance $ 500,000 $ 250,000 Unamortized debt discount (13,248 ) (22,622 ) Unamortized debt premium 102,527 - Outstanding, net of debt discount and premium $ 589,279 $ 227,378

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Schedule of company's common stock warrants activity	Weighted Weighted- Warrants/ Exercise Expected Outstanding as of January 1, 2018 - $ - - Granted 208,333 0.60 5.0 Exercised - - - Forfeited/Canceled - - - Outstanding as of December 31, 2018 208,333 $ 0.60 4.8 Granted 208,333 0.60 5.0 Exercised - - - Forfeited/Canceled - - - Outstanding as of September 30, 2019 416,666 $ 0.60 4.2 Weighted Weighted- Warrants/ Exercise Expected Outstanding as of January 1, 2018 - $ - - Granted - - - Exercised - - - Forfeited/Canceled - - - Outstanding as of December 31, 2018 - $ - - Granted 293,000 1.01 3.0 Exercised - - - Forfeited/Canceled - - - Outstanding as of September 30, 2019 293,000 $ 1.01 2.9

Stock Option Plan and Stock-B_2

Stock Option Plan and Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Summary of fair value of stock awards granted	Shares Fair Value Weighted Shares Granted as of December 31, 2018 - $ - $ - Shares Granted 571,000 0.27 - 1.49 0.99 Shares Issued 108,000 0.27 - 1.49 0.32 Shares Granted not Issued as of September 30, 2019 463,000 $ 0.75 - 1.39 $ 1.15
Summary of stock options granted valuation assumptions	2019 Risk-free interest rate 1.68 - 2.31 % Expected dividend yield 0 % Volatility factor (weekly) 126.89 % Expected life of option 3 years
Summary of stock option activity	Shares Exercise Weighted Outstanding as of December 31, 2018 - $ - $ - Granted 293,000 0.95 - 1.21 1.01 Exercised - - - Options forfeited/cancelled - - - Outstanding as of September 30, 2019 293,000 $ 0.95 - 1.21 $ 1.01
Summary of stock options vested or expected to vest	Options Outstanding Exercisable Options Exercise Number of Options Weighted Average Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic $ 0.95 200,000 $ 0.95 2.95 $ - 200,000 $ 0.95 2.93 $ - 1.09 3,000 1.09 2.75 - 3,000 1.09 2.75 - 1.10 45,000 1.10 2.84 - 45,000 1.10 2.84 - 1.21 45,000 1.21 2.58 - 45,000 1.21 2.58 - $ 1.03-1.21 293,000 $ 1.01 2.88 $ - 293,000 $ 1.01 2.88 $ -
Summary of non-vested stock options	Number of Weighted- Non-vested as of December 31, 2018 - $ - Granted 293,000 0.78 Forfeited - - Vested 293,000 0.78 Non-vested as of September 30, 2019 - $ -

Subsequent Events (Tables)

Subsequent Events (Tables)	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Schedule of convertible note payable	Debtor Date of Maturity Principal Net Interest Warrants Issued Term Exercise Amortization Debt GS Capital Partners LLC 10/30/2019 10/29/2019 $ 125,000 $ 109,500 4 % 50,000 5 $ 2.00 $ 23,867 $ 15,500 Power Up Lending Group Ltd. 10/24/2019 10/23/2020 106,000 100,000 8 % - - - - 6,000 Peak One Opportunity Fund, L.P. 10/23/2019 10/22/2020 120,000 103,000 0 % 50,000 5 2.00 21,606 17,000 Tangiers Global, LLC 10/23/2019 10/22/2020 106,300 100,000 8 % 50,000 5 2.00 21,116 6,300 $ 457,300 $ 412,500 150,000 $ 66,589 $ 44,800

Background and Organization (De

Background and Organization (Details) - $ / shares	Sep. 30, 2019	Dec. 31, 2018	Sep. 21, 2018	Oct. 05, 2017
Background and Organization (Textual)
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Delaware [Member]
Background and Organization (Textual)
Common stock, par value			$ 0.001	$ 0.0001
Common stock, shares authorized			300,000,000	95,000,000
Preferred stock, par value			$ 0.001	$ 0.0001
Preferred stock, shares authorized			50,000,000	5,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Stock-based compensation expense	$ 840,438
Un-issued shares liability	$ 532,418
Stock Option [Member]
Options outstanding	293,000
Fair market value of stock options	$ 228,058
Fair market value of shares issued	108,000
Stock-based compensation expense	$ 34,600
Fair market value of additional shares	463,000
Un-issued shares liability	$ 532,418
Stock Option [Member] | Warrant [Member]
Warrants outstanding	416,666		208,333
Options outstanding	293,000

Going Concern and Management'_2

Going Concern and Management's Liquidity Plans (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Going Concern and Management's Liquidity Plans (Textual)
Cash	$ 33,226	$ 2,831	$ 36,411	$ 110
Negative working capital	1,180,640
Cumulative net losses	1,578,648		$ 382,830
Proceeds from issuance of debt	222,250
Cash proceeds issuance of common stock	$ 20,000

Accounts Payables and Accrued_3

Accounts Payables and Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
Accounts Payables related party		$ 10,900
Professional fees	72,603	19,175
Interest	17,113	3,722
Taxes		400
Other Accounts Payables	2,453	150
Un-issued shares liability	532,418
Convertible Note Payables	589,279	227,378
Total	$ 1,213,866	$ 261,725

Accounts Payables and Accrued_4

Accounts Payables and Accrued Expenses and Other Current Liabilities (Details Textual) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Accounts Payables and Accrued Expenses and Other Current Liabilities (Textual)
Prepaid Expenses		$ 10,900

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - Convertible notes payable [Member] - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Principal balance	$ 500,000	$ 250,000
Unamortized debt discount	(13,248)	(22,622)
Unamortized debt premium	102,527
Outstanding, net of debt discount and premium	$ 589,279	$ 227,378

Convertible Notes Payable (De_2

Convertible Notes Payable (Details Textual) - USD ($)	May 30, 2019	Oct. 24, 2018	Aug. 22, 2019	Jul. 18, 2019	Feb. 25, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Feb. 15, 2019	Dec. 31, 2018
Convertible Notes Payable (Textual)
Common stock per share						$ 0.001		$ 0.001			$ 0.001
Interest expense						$ 10,002		$ 26,891
Additional paid-in capital						312,701		312,701			$ 72,412
Convertible notes payable [Member]
Convertible Notes Payable (Textual)
Principal balance						457,300		457,300
Auctus Note #1 [Member]
Convertible Notes Payable (Textual)
Debt discount						20,853		20,853
Common stock per share		$ 0.001
Expiration date		Oct. 23, 2019
Convertible note, description		(i) 180 days from the date of the Auctus Note #1, or (ii) upon effective date of a registration statement. The conversion price of the Auctus Note #1 is equal to the lesser of: (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #1 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Auctus Note #1 was funded on October 29, 2018, when the Company received proceeds of $222,205, after disbursements for the lender's transaction costs, fees and expenses which in aggregate resulted in a total discount of $27,795 to be amortized to interest expense over the life of the Auctus Note #1.
Determined warrants derivative, description		The Company has determined that the Warrants are exempt from derivative accounting and were valued at $101,937 on the Date of Inception using the Black Scholes Options Pricing Model. Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.49 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 251% and (5) risk free interest rate of 2.51%. The note proceeds of $250,000 were then allocated between the fair value of the Auctus Note #1 ($250,000) and the Warrants ($101,937), resulting in a debt discount of $72,412.
Principal balance		$ 250,000
Stated interest		8.00%
Debt premium		$ 343,796
Common stock purchase warrants issued	25,000		25,000	25,000
Accreted premium to additional paid-in capital						306,820		306,820
Auctus Note #1 [Member] | Convertible notes payable [Member]
Convertible Notes Payable (Textual)
Common stock per share		$ 0.001
Expiration date		Oct. 23, 2023
Convertible note, description		"if-converted" rate of $0.20 per share (lowest trading price during the 20 days preceding the note's issuance), which computed to 1,211,828 shares of 'if-converted' common stock with a redemption value of $593,796 due to $0.49 per share fair market value of the Company's stock on the Auctus Note #1's date of issuance.
Warrants exercise price		$ 0.60
Common stock purchase warrants issued		208,333
Auctus Note #2 [Member]
Convertible Notes Payable (Textual)
Common stock per share					$ 0.60					$ 0.60
Expiration date					Feb. 24, 2024
Convertible note, description					The Company has determined that the Warrants are exempt from derivative accounting and were valued at $55,417 on the Date of Inception using the Black Scholes Options Pricing Model.  Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.27 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 358% and (5) risk free interest rate of 2.48%.  The Auctus Note #2 proceeds of $250,000 were then allocated between the fair value of the Auctus Note #2 ($250,000) and the Warrants ($55,417), resulting in a debt discount of $45,361.
Common stock purchase warrants issued					208,333
Interest expense								16,271
Additional paid-in capital						$ 16,949		$ 16,949
Auctus Note #2 [Member] | Secured Promissory Note [Member]
Convertible Notes Payable (Textual)
Convertible notes issued					$ 27,750
Common stock per share					$ 0.001
Expiration date					Feb. 24, 2020
Convertible note, description					(i) 180 days from the date of the Auctus Note #2 or (ii) upon effective date of a new registration statement. The conversion price of the Auctus Note #2 is equal to the lesser of: (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #2 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Company may prepay the Auctus Note #2 at any time at a rate of 120% of outstanding principal and interest during the first 90 days it is outstanding and 130% of outstanding principal and interest for the next 90 days thereafter. Thereafter the prepayment amount increases 5% for each thirty-day period until 270 days from the issue date at which time it is fixed at 150% of the outstanding principal and interest on the Auctus Note #2.
Principal balance					$ 250,000
Stated interest					8.00%
Net proceeds					$ 222,250
Additional conversion description					The Company recorded a premium of $82,500 as a reduction to additional paid-in capital based on a discounted "if-converted" rate of $0.20 per share (lowest trading price during the 20 days preceding the note's issuance), which computed to 1,250,000 shares of 'if-converted' common stock with a redemption value of $332,500 due to $0.266 per share fair market value of the Company's stock on the Auctus Note #2's date of issuance.

Stockholders' Equity (Details)

Stockholders' Equity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Stock Option [Member]
Number of shares, Outstanding, Beginning balance
Number of shares, granted	293,000
Number of shares, Outstanding, Ending balance	293,000
Weighted-Average Exercise Price, Outstanding, Beginning balance
Weighted-Average Exercise Price, granted	1.01
Weighted-Average Exercise Price, Outstanding, Ending balance	$ 1.01
Weighted-Average Remaining Expected Term, Beginning balance	0 years	0 years
Weighted-Average Remaining Expected Term, Options granted	3 years
Weighted-Average Remaining Expected Term, Ending balance	2 years 10 months 25 days	0 years
Warrant [Member]
Number of shares, Outstanding, Beginning balance	208,333
Number of shares, granted	208,333	208,333
Number of shares, exercised
Number of shares, Forfeited/Cancelled
Number of shares, Outstanding, Ending balance	416,666	208,333
Weighted-Average Exercise Price, Outstanding, Beginning balance	$ 0.60
Weighted-Average Exercise Price, granted	0.60	0.60
Weighted-Average Exercise Price, exercised
Weighted-Average Exercise Price, Forfeited/Cancelled
Weighted-Average Exercise Price, Outstanding, Ending balance	$ 0.60	$ 0.60
Weighted-Average Remaining Expected Term, Beginning balance	4 years 9 months 18 days	0 years
Weighted-Average Remaining Expected Term, Options granted	5 years	5 years
Weighted-Average Remaining Expected Term, Ending balance	4 years 2 months 12 days	4 years 2 months 12 days

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Aug. 20, 2019	May 30, 2019	Aug. 22, 2019	Jul. 18, 2019	May 17, 2019	Feb. 25, 2019	Nov. 02, 2018	Jul. 30, 2018	Jul. 09, 2019	Sep. 30, 2019	Dec. 31, 2018
Stockholders' Equity (Textual)
Description of reverse stock split								The Company authorized a reverse split that resulted in a reduction of the number of outstanding and issued shares of both common and preferred stock so that after the split became effective on August 13, 2018, the shares of both common and preferred stock were reduced to 1 share for each 30 shares currently issued and outstanding. The effect on the Balance Sheet is a transfer of value from stock value at par to Additional Paid-in Capital. As a result of the one (1) for thirty (30) reverse stock split, the Company will continue to be authorized to issue 300,000,000 shares of Common Stock, and 50,000,000 shares of Preferred Stock.
Preferred stock, shares issued
Common stock, shares issued										85,306,673	85,103,673
Common stock, shares outstanding										85,306,673	85,103,673
Warrant [Member]
Stockholders' Equity (Textual)
Share price										$ 2
2010 Stock Plan [Member]
Stockholders' Equity (Textual)
Conversion of accrued interest					$ 34,600		$ 34,600
Shares issued for conversion of accrued interest, shares					108,000		108,000
Share price					$ 0.32		$ 0.32
Options granted									293,000
Options total fair value at the time of award									$ 228,058
Stock Option [Member] | Warrant [Member]
Stockholders' Equity (Textual)
Warrants as part of a convertible note agreement						208,333
Debt discount						$ 45,361
Auctus Note #1 [Member]
Stockholders' Equity (Textual)
Conversion of accrued interest		$ 5,000	$ 5,000	$ 5,000
Shares issued for conversion of accrued interest, shares		25,000	25,000	25,000
Share price		$ 0.20	$ 0.20	$ 0.20
Active S-1 [Member]
Stockholders' Equity (Textual)
Conversion of accrued interest	$ 20,000
Shares issued for conversion of accrued interest, shares	20,000
Share price	$ 1

Stock Option Plan and Stock-B_3

Stock Option Plan and Stock-Based Compensation (Details) - Stock Awards Plan [Member]	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Shares Granted as of December 31, 2018 | shares
Shares Granted | shares	571,000
Shares Issued | shares	108,000
Shares Granted not Issued as of September 30, 2019 | shares	463,000
Fair Value per Share, Shares Granted
Weighted Average Market Value per Share, Shares Granted as of December 31, 2018
Weighted Average Market Value per Share, Shares Granted	0.99
Weighted Average Market Value per Share, Shares Issued	0.32
Weighted Average Market Value per Share, Shares Granted as of September 30, 2019	1.15
Minimum [Member]
Fair Value per Share, Shares Granted	0.27
Fair Value per Share, Shares Issued	0.27
Fair Value per Share, Shares Granted not Issued	0.75
Maximum [Member]
Fair Value per Share, Shares Granted	1.49
Fair Value per Share, Shares Issued	1.49
Fair Value per Share, Shares Granted not Issued	$ 1.39

Stock Option Plan and Stock-B_4

Stock Option Plan and Stock-Based Compensation (Details 1)	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Risk-free interest rate, Minimum	1.68%
Risk-free interest rate, Maximum	2.31%
Expected dividend yield	0.00%
Volatility factor (weekly)	126.89%
Expected life of option	3 years

Stock Option Plan and Stock-B_5

Stock Option Plan and Stock-Based Compensation (Details 2) - Stock Option [Member]	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Number of shares, Outstanding, Beginning balance | shares
Granted | shares	293,000
Exercised | shares
Options forfeited/cancelled | shares
Number of shares, Outstanding, Ending balance | shares	293,000
Exercise Price per Share, Outstanding as of December 31, 2018
Exercise Price per Share, Exercised
Exercise Price per Share, Options forfeited/cancelled
Exercise Price per Share, Outstanding as of September 30, 2019
Weighted-Average Exercise Price, Outstanding, Beginning balance
Weighted Average Exercise Price per Share, Granted	1.01
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Options forfeited/cancelled
Weighted-Average Exercise Price, Outstanding, Ending balance	1.01
Minimum [Member]
Exercise Price per Share, Granted	0.95
Exercise Price per Share, Outstanding as of September 30, 2019	0.95
Maximum [Member]
Exercise Price per Share, Granted	1.21
Exercise Price per Share, Outstanding as of September 30, 2019	$ 1.21

Stock Option Plan and Stock-B_6

Stock Option Plan and Stock-Based Compensation (Details 3)	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Exercise Price, Lower Range Limit	$ 1.03
Exercise Price, Upper Range Limit	$ 1.21
Options Outstanding, Number of Options | shares	293,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.01
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 10 months 17 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	293,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.01
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 10 months 17 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 0.95 [Member]
Options Outstanding, Number of Options | shares	200,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.95
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 11 months 12 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	200,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.95
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 11 months 4 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 1.09 [Member]
Options Outstanding, Number of Options | shares	3,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.09
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 9 months
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	3,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.09
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 9 months
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 1.10 [Member]
Options Outstanding, Number of Options | shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.10
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 10 months 3 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.10
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 10 months 3 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 1.21 [Member]
Options Outstanding, Number of Options | shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.21
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 6 months 29 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.21
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 6 months 29 days
Exercisable Options, Aggregate Intrinsic Value | $

Stock Option Plan and Stock-B_7

Stock Option Plan and Stock-Based Compensation (Details 4) - Stock Options [Member]	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Number of Options, Non-vested as of December 31, 2018 | shares
Number of Options, Non-vested Granted | shares	293,000
Number of Options, Non-vested Forfeited | shares
Number of Options, Vested | shares	293,000
Number of Options, Non-vested as of September 30, 2019 | shares
Weighted-Average Grant-Date Fair Value, Non-vested as of December 31, 2018 | $ / shares
Weighted-Average Grant-Date Fair Value, Granted | $ / shares	0.78
Weighted-Average Grant-Date Fair Value, Forfeited | $ / shares
Weighted-Average Grant-Date Fair Value, Vested | $ / shares	0.78
Weighted-Average Grant-Date Fair Value, Non-vested as of December 31, 2018 | $ / shares

Stock Option Plan and Stock-B_8

Stock Option Plan and Stock-Based Compensation (Details Textual)	Aug. 09, 2019USD ($)Persons$ / sharesshares	Jul. 16, 2019USD ($)Persons$ / sharesshares	Jul. 15, 2019USD ($)Persons$ / sharesshares	Jul. 09, 2019USD ($)$ / sharesshares	Jun. 11, 2019USD ($)Persons$ / sharesshares	May 17, 2019USD ($)Persons$ / sharesshares	May 10, 2019USD ($)Persons$ / sharesshares	May 01, 2019USD ($)$ / sharesshares	Mar. 11, 2019USD ($)Persons$ / sharesshares	Mar. 07, 2019USD ($)Persons$ / sharesshares	Nov. 29, 2018USD ($)Persons$ / sharesshares	Nov. 06, 2018USD ($)Persons$ / sharesshares	Nov. 02, 2018USD ($)Persons$ / sharesshares	Aug. 01, 2019USD ($)$ / sharesshares	Jul. 31, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)shares	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)shares	Dec. 31, 2010	Dec. 31, 2018shares
Stock Option Plan and Stock Based Compensation (Textual)
Shares granted not issued, value																	$ 532,418
Aggregate intrinsic value of options exercised
Share-based Payment Arrangement, Option [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options outstanding number | shares																293,000	293,000
Options granted | shares																	293,000
Grants in period, weighted average grant date fair value | $ / shares																	$ 0.78
Stock-based compensation expense																$ 228,058	$ 228,058
Stock options exercised | shares
Board of Members [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares						4,000							4,000
Grants in period, weighted average grant date fair value | $ / shares						$ 1.49							$ 0.51
Number of persons | Persons						4							4
Options granted, value						$ 5,960							$ 2,040
Consultant [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares									100,000
Grants in period, weighted average grant date fair value | $ / shares									$ 0.27
Number of persons | Persons									1
Options granted, value									$ 26,600
Members Audit Committee [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares	2,000						3,000			3,000	4,000	1,000
Grants in period, weighted average grant date fair value | $ / shares	$ 0.80						$ 1			$ 0.27	$ 1	$ 0.52
Number of persons | Persons	2						3			3	4	1
Options granted, value	$ 1,600						$ 3,000			$ 810	$ 4,000	$ 520
Financial Advisory Board [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares		100,000	100,000		250,000
Grants in period, weighted average grant date fair value | $ / shares		$ 1	$ 0.75		$ 1.39
Number of persons | Persons		1	1		1
Options granted, value		$ 100,000	$ 75,000		$ 347,500
Financial Advisory Board [Member] | Share-based Payment Arrangement, Option [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares				200,000
Grants in period, weighted average grant date fair value | $ / shares				$ 0.95
Options granted, value				$ 141,060
Terms of award				Three-year options
Medical Advisory Board [Member] | Share-based Payment Arrangement, Option [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares								45,000						45,000	3,000
Grants in period, weighted average grant date fair value | $ / shares								$ 1.21						$ 1.10	$ 1.09
Options granted, value								$ 44,820						$ 39,731	$ 2,447
Terms of award								Three-year options						Three-year options	Three-year options
2010 Stock Plan [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Stock appreciation rights percentage																			15.00%
Options outstanding number | shares																293,000	293,000
Options granted, value																	$ 228,058
Shares issued for services | shares																	108,000
Shares issued for services, value																	$ 34,600
Shares not yet issued for services | shares																	463,000
Shares not yet issued for services, value																	$ 532,418
Stock-based compensation expense																$ 34,600	$ 34,600
Weighted-average remaining contractual life options exercisable																	2 years 10 months 17 days
Aggregate intrinsic value for fully vested, exercisable options																0	$ 0
Aggregate intrinsic value of options exercised																$ 0	$ 0
Tax benefit realized from stock option exercises																		$ 0
Stock options exercised | shares
Options or stock awards available for grant under the 2010 Plan | shares																11,901,551	11,901,551

Commitments and Contingencies (

Commitments and Contingencies (Details)	Sep. 30, 2019USD ($)
Commitments and Contingencies (Textual)
Payment of severance upon termination	$ 100,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Debt discount	$ 13,794		$ 37,124
Convertible notes payable [Member]
Principal Amount	457,300		457,300
Net Received	412,500		$ 412,500
Warrants Issued			150,000
Amortization of Warrants			$ 66,859
Debt discount			$ 44,800
Convertible notes payable [Member] | GS Capital Partners LLC [Member]
Debtor			GS Capital Partners LLC
Date of Issuance			Oct. 30, 2019
Maturity Date			Oct. 29, 2019
Principal Amount	125,000		$ 125,000
Net Received	$ 109,500		$ 109,500
Interest			4.00%
Warrants Issued			50,000
Term			5 years
Exercise Price	$ 2		$ 2
Amortization of Warrants			$ 23,867
Debt discount			$ 15,500
Convertible notes payable [Member] | Power Up Lending Group Ltd [Member]
Debtor			Power Up Lending Group Ltd.
Date of Issuance			Oct. 24, 2019
Maturity Date			Oct. 23, 2020
Principal Amount	$ 106,000		$ 106,000
Net Received	$ 100,000		$ 100,000
Interest			8.00%
Warrants Issued
Exercise Price
Amortization of Warrants
Debt discount			$ 6,000
Convertible notes payable [Member] | Peak One Opportunity Fund, L.P.[Member]
Debtor			Peak One Opportunity Fund, L.P.
Date of Issuance			Oct. 23, 2019
Maturity Date			Oct. 22, 2020
Principal Amount	$ 120,000		$ 120,000
Net Received	$ 103,000		$ 103,000
Interest			0.00%
Warrants Issued			50,000
Term			5 years
Exercise Price	$ 2		$ 2
Amortization of Warrants			$ 21,606
Debt discount			$ 17,000
Convertible notes payable [Member] | Tangiers Global, LLC [Member]
Debtor			Tangiers Global, LLC
Date of Issuance			Oct. 23, 2019
Maturity Date			Oct. 22, 2020
Principal Amount	$ 106,300		$ 106,300
Net Received	$ 100,000		$ 100,000
Interest			8.00%
Warrants Issued			50,000
Term			5 years
Exercise Price	$ 2		$ 2
Amortization of Warrants			$ 21,116
Debt discount			$ 6,300

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)

Nov. 11, 2019

Nov. 08, 2019

Oct. 17, 2019

Oct. 08, 2019

Oct. 03, 2019

Oct. 01, 2019

Mar. 11, 2019

Nov. 08, 2019

Nov. 01, 2019

Oct. 21, 2019

May 17, 2019

Feb. 25, 2019

Nov. 02, 2018

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Subsequent Events (Textual)

Option term

3 years

Fair value

$ 457,300

Debt discount

$ 13,794

37,124

Consultant [Member]

Subsequent Events (Textual)

Granted shares

100,000

2010 Stock Plan [Member]

Subsequent Events (Textual)

Conversion of accrued interest

$ 34,600

$ 34,600

Shares issued for conversion of accrued interest, shares

108,000

108,000

Share price

$ 0.32

$ 0.32

Auctus Note 2 [Member]

Subsequent Events (Textual)

Shares issued for conversion of accrued interest, shares

208,333

Convertible notes payable [Member]

Subsequent Events (Textual)

Face value

457,300

457,300

Net proceeds

$ 412,500

412,500

Debt discount

$ 44,800

Warrants Issued

150,000

Subsequent events [Member] | 2010 Stock Plan [Member]

Subsequent Events (Textual)

Value of shares issued for short term liabilities

$ 532,418

Shares issued for short term liabilities

463,000

Subsequent events [Member] | 2010 Stock Plan [Member] | IR agreement [Member]

Subsequent Events (Textual)

Granted shares

250,000

Share price

$ 0.51

Fair value

$ 127,500

Subsequent events [Member] | 2010 Stock Plan [Member] | Board of Directors [Member]

Subsequent Events (Textual)

Granted shares

3,000

3,000

Share price

$ 0.65

$ 0.60

$ 0.65

Fair value

$ 1,950

$ 1,800

Subsequent events [Member] | 2010 Stock Plan [Member] | Medical Advisory Board Member [Member]

Subsequent Events (Textual)

Granted shares

3,000

45,000

Option term

3 years

3 years

Share price

$ 0.73

$ 0.61

Fair value

$ 1,635

$ 27,450

Subsequent events [Member] | 2010 Stock Plan [Member] | Consultant [Member]

Subsequent Events (Textual)

Granted shares

300,000

Share price

$ 0.55

Fair value

$ 166,283

Subsequent events [Member] | Convertible notes payable [Member]

Subsequent Events (Textual)

Conversion price

$ 0.001

$ 0.001

Face value

$ 457,300

$ 457,300

Net proceeds

$ 412,500

$ 412,500

Debt, description

(i) 180 days from the date of the Note or (ii) upon effective date of a registration statement. The conversion price of the Notes is equal to 65% of the lowest trading price at close during the twenty days prior to a conversion notice. The debt discount of $44,800 is amortized over the duration of the loans. One of the SPA's includes an option to raise an additional $350,000 in convertible notes. The Debentures permit the Company to pre-pay its obligations at a premium prior to maturity.

Warrant [Member]

Subsequent Events (Textual)

Granted shares

208,333

208,333

Share price

$ 2

$ 2

Fair value

$ 457,300

Face value

$ 82,200

82,200

Debt discount

$ 66,589

Warrants term

5 years

Common Stock [Member] | Auctus Note 1 [Member]

Subsequent Events (Textual)

Conversion price

$ 0.20

Common Stock [Member] | Subsequent events [Member] | Auctus Note 2 [Member]

Subsequent Events (Textual)

Conversion of accrued interest

$ 12,000

Shares issued for conversion of accrued interest, shares

100,000

Conversion price

$ 0.12

$ 0.12

Common Stock [Member] | Subsequent events [Member] | Auctus Note 1 [Member]

Subsequent Events (Textual)

Conversion of accrued interest

$ 10,000

Shares issued for conversion of accrued interest, shares

50,000